The SPORE Tissue Procurement and Analysis Facility (TPA) provides centralized, quality controlled quality assured procurement, processing, analysis, storage and distribution of normal and malignant breast tissue from UNC Hospitals. Whenever possible, corresponding serum and plasma are also obtained. All procured specimens are reviewed by the Facility Pathologist to ensure that representative tissue is banked and distributed. We have recently expanded our tissue procurement activities to Rex Hospital, a large hospital in Raleigh, N.C., recently purchased by the UNC Health Care System. This effectively doubles our access to breast cancer specimens. In addition to procurement services, the facility provides tissue sectioning for frozen and paraffin embedded specimens, immunohistochemistry and fluorescence in situ assays and access to state-of-the-art tissue-based technology, including laser-capture microdissection. Expert personnel provide consultation and training to faculty and staff in these applications. The facility also serves as a central clearing house for the Carolina Breast Cancer Study--banking and distributing unstained sections for multiple assays. Customized databases serve to monitor and survey all of these specimens, providing a coordinated system of quality control, sample tracking and distribution of specimens to appropriate investigators. The TPA has implemented policies and procedures to support these services and address technical, medical and legal issues, as well as protection of patient privacy and confidentiality. These policies developed in collaboration with area pathologists have contributed to the excellent compliance of block submission for the large population-based studies. The facility supports all of the SPORE projects and developmental studies, working with each individual investigator to accommodate their special research needs. The facility will also be the central site for tissue banking, IHC and FISH assays for the InterSPORE Neoadjuvant study.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-10
Application #
6659188
Study Section
Project Start
2002-09-13
Project End
2003-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
10
Fiscal Year
2002
Total Cost
$168,504
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386
Nasarre, Patrick; Bonilla, Ingrid V; Metcalf, John S et al. (2018) TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res 28:185-194
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Couture, Heather D; Williams, Lindsay A; Geradts, Joseph et al. (2018) Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. NPJ Breast Cancer 4:30
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12

Showing the most recent 10 out of 598 publications